Impact of Prestroke Oral Anticoagulation on Severity and Outcome of Ischemic and Hemorrhagic Stroke in Patients with Atrial Fibrillation

被引:20
作者
Audebert, Heinrich J. [1 ]
Schenk, Berit [2 ]
Schenkel, Johannes [2 ]
Heuschmann, Peter U. [1 ]
机构
[1] Charite, Ctr Stroke Res, DE-12200 Berlin, Germany
[2] Stadt Klinikum Munchen GmbH, Klinikum Harlaching, Dept Neurol, Munich, Germany
关键词
Stroke; Atrial fibrillation; Oral anticoagulation; Stroke severity; TELEMEDIC PILOT PROJECT; ANTITHROMBOTIC AGENTS; CARE TEMPIS; WARFARIN; PREVENTION; MORTALITY; THERAPY; IMPLEMENTATION; FREQUENCY; SURVIVAL;
D O I
10.1159/000297963
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Stroke prevention with oral anticoagulation is effective in patients with atrial fibrillation. An additional beneficial effect of oral anticoagulation prior to the event on stroke severity and prognosis was suggested in ischemic strokes. We tested whether this benefit is preserved after inclusion of hemorrhagic strokes and adjustment for prestroke living conditions. Methods: Data were used from a prospective hospital-based intervention trial evaluating quality of care and outcome in ten district hospitals. All ischemic and hemorrhagic stroke patients with atrial fibrillation were included. We analyzed separate multivariable regression models to identify factors associated with prescription of oral anticoagulation before stroke and to investigate the independent effect of anticoagulation on admission stroke severity, 3-month mortality and functional outcome. Results: The analysis comprised 804 (718 ischemic, 86 hemorrhagic) stroke patients admitted between July 2003 and March 2005. Males, patients aged 65-84, living independently, with diabetes, previous cerebrovascular event or additional high cardioembolic risks were more likely to receive oral anticoagulation before admission. Admission international normalized ratio (INR) between 2 and 3 (OR 0.35, 95% CI: 0.17-0.71) or higher (OR 0.32, 95% CI: 0.11-0.92) was associated with less severe strokes (including hemorrhagic strokes) compared with INR <2. Anticoagulation was associated with decreased risk of death and poor functional outcome (modified Rankin Scale >3) at 3 months (OR 0.54, 95% CI: 0.36-0.84, and OR 0.70, 95% CI: 0.47-1.06). After adjustment for stroke severity, anticoagulation had no additional effect on mortality and functional outcome. Conclusions: The beneficial effect of prestroke anticoagulation on stroke outcome related to the reduced stroke severity is not offset by adverse effects in hemorrhagic stokes. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:476 / 483
页数:8
相关论文
共 27 条
[1]   Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks [J].
Aguilar, Maria I. ;
Hart, Robert .
STROKE, 2008, 39 (04) :1399-1400
[2]   Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks [J].
Aguilar, MI ;
Hart, R .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03)
[3]   Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants - Results from a Danish quality-control registry of 22 179 patients with ischemic stroke [J].
Andersen, Klaus Kaae ;
Olsen, Tom Skyhoj .
STROKE, 2007, 38 (02) :259-263
[4]   Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany [J].
Audebert, Heinrich J. ;
Schenkel, Johannes ;
Heuschmann, Peter U. ;
Bogdahn, Ulrich ;
Haberl, Roman L. .
LANCET NEUROLOGY, 2006, 5 (09) :742-748
[5]   Can telemedicine contribute to fulfill WHO Helsingborg Declaration of specialized stroke care? The Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria [J].
Audebert, HJ ;
Wimmer, MLJ ;
Hahn, R ;
Schenkel, J ;
Bogdahn, U ;
Horn, M ;
Haberl, RL .
CEREBROVASCULAR DISEASES, 2005, 20 (05) :362-369
[6]   Admission International Normalized Ratio and Acute Infarct Volume in Ischemic Stroke [J].
Ay, Hakan ;
Arsava, Ethem Murat ;
Gungor, Levent ;
Greer, David ;
Singhal, Aneesh B. ;
Furie, Karen L. ;
Koroshetz, Walter J. ;
Sorensen, A. Gregory .
ANNALS OF NEUROLOGY, 2008, 64 (05) :499-506
[7]   Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study [J].
Deplanque, D ;
Leys, D ;
Parnetti, L ;
Schmidt, R ;
Ferro, J ;
De Reuck, J ;
Mas, JL ;
Gallai, V .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) :798-806
[8]   Secondary prevention of stroke in patients with atrial fibrillation: Factors influencing the prescription of oral anticoagulation at discharge [J].
Deplanque, Dominique ;
Leys, Didier ;
Parnetti, Lucilla ;
Schmidt, Reinhold ;
Ferro, Jose ;
de Reuck, Jacques ;
Mas, Jean-Louis ;
Gallai, Virgilio .
CEREBROVASCULAR DISEASES, 2006, 21 (5-6) :372-379
[9]  
EAFT (European Atrial Fibrillation Trial) Study Group, 1993, Lancet, V342, P1255
[10]   Death and disability from warfarin-associated intracranial and extracranial hemorrhages [J].
Fang, Margaret C. ;
Go, Alan S. ;
Chang, Yuchiao ;
Hylek, Elaine M. ;
Henault, Lori E. ;
Jensvold, Nancy G. ;
Singer, Daniel E. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) :700-705